Merriman Capital Initiates on BioLight Life Sciences Investments Ltd. with a Buy Rating
SAN FRANCISCO - October 30, 2014 - Merriman Capital, Inc. ("Merriman"), a wholly owned subsidiary of Merriman Holdings, Inc. (MERR), announced that it has initiated equity research coverage of BioLight Life Sciences Investments Ltd. (BLGTY) with a Buy rating and a $12.00 price target.
BioLight is an early-stage biomed company led by a blue-chip board and seasoned management team. Headquartered in Tel Aviv, Israel, BioLight Life Sciences Investments Ltd. (www.bio-light.co.il) invests in, manages and commercializes biomedical innovations. The company leverages a unique organizational model: investing in early stage companies with technology solutions grouped around specific medical conditions in order to share key resources, facilitate innovation, and speed time to market. The two current portfolio areas are in ophthalmology and in cancer diagnostics. In March, 2014, BioLight`s Level I ADRs began trading over-the-counter in the U.S. (BLGTY). Each ADR equates to 100 underlying shares, which are traded on the Tel-Aviv Stock Exchange (BOLT.TA) which is the primary Stock Market of BioLight`s shares.
